1. Home
  2. GBR vs REVB Comparison

GBR vs REVB Comparison

Compare GBR & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Concept Energy Inc

GBR

New Concept Energy Inc

HOLD

Current Price

$0.77

Market Cap

4.3M

Sector

Energy

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.96

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBR
REVB
Founded
1978
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GBR
REVB
Price
$0.77
$0.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.8K
114.0K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$153,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.08
N/A
52 Week Low
$0.67
$0.83
52 Week High
$1.78
$60.48

Technical Indicators

Market Signals
Indicator
GBR
REVB
Relative Strength Index (RSI) 43.41 42.53
Support Level $0.75 $1.03
Resistance Level $0.85 $1.20
Average True Range (ATR) 0.05 0.10
MACD 0.01 0.03
Stochastic Oscillator 13.44 34.22

Price Performance

Historical Comparison
GBR
REVB

About GBR New Concept Energy Inc

New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: